Prospective Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma (HNSCCa)

Trial Profile

Prospective Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma (HNSCCa)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs MEDI 0457 (Primary)
  • Indications Head and neck cancer; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 28 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
    • 14 Nov 2016 According to an Inovio Pharmaceuticals media release, company expects multiple reports of additional data throughout 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top